NK-One Therapeutics

NK-One Therapeutics is a Hong Kong-based biotechnology company specializing in the development of next-generation Natural Killer (NK) cell therapies for the treatment of cancer. Spun out from the University of Hong Kong, the company utilizes a proprietary platform to expand and activate NK cells, significantly enhancing their ability to target and eliminate tumor cells. Their pipeline focuses on addressing the limitations of current immunotherapies in both solid tumors and hematological malignancies. The company is currently in the pre-clinical stage, advancing its lead candidates toward IND-enabling studies and clinical trials. NK-One aims to provide a more accessible and effective "off-the-shelf" cell therapy solution for oncology patients.